Copyright Reports & Markets. All rights reserved.

Global Personalized Medicine and Epigenomics Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Request for Sample of this report
Buy now

Table of Contents

    1 Personalized Medicine and Epigenomics Market Overview

    • 1.1 Product Overview and Scope of Personalized Medicine and Epigenomics
    • 1.2 Classification of Personalized Medicine and Epigenomics by Types
      • 1.2.1 Global Personalized Medicine and Epigenomics Revenue Comparison by Types (2019-2024)
      • 1.2.2 Global Personalized Medicine and Epigenomics Revenue Market Share by Types in 2018
      • 1.2.3 Reagents
      • 1.2.4 Kits
      • 1.2.5 Instruments
      • 1.2.6 Enzymes
      • 1.2.7 Services
    • 1.3 Global Personalized Medicine and Epigenomics Market by Application
      • 1.3.1 Global Personalized Medicine and Epigenomics Market Size and Market Share Comparison by Applications (2014-2024)
      • 1.3.2 Oncology
      • 1.3.3 Non-Oncology
      • 1.3.4 Cancer Drug Technology
    • 1.4 Global Personalized Medicine and Epigenomics Market by Regions
      • 1.4.1 Global Personalized Medicine and Epigenomics Market Size (Million USD) Comparison by Regions (2014-2024)
      • 1.4.1 North America (USA, Canada and Mexico) Personalized Medicine and Epigenomics Status and Prospect (2014-2024)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Personalized Medicine and Epigenomics Status and Prospect (2014-2024)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Personalized Medicine and Epigenomics Status and Prospect (2014-2024)
      • 1.4.4 South America (Brazil, Argentina, Colombia) Personalized Medicine and Epigenomics Status and Prospect (2014-2024)
      • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Personalized Medicine and Epigenomics Status and Prospect (2014-2024)
    • 1.5 Global Market Size of Personalized Medicine and Epigenomics (2014-2024)

    2 Manufacturers Profiles

    • 2.1 Abbott Laboratories
      • 2.1.1 Business Overview
      • 2.1.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 Abbott Laboratories Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.2 Affymetrix
      • 2.2.1 Business Overview
      • 2.2.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.2.2.1 Product A
        • 2.2.2.2 Product B
      • 2.2.3 Affymetrix Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.3 Agilent Technologies
      • 2.3.1 Business Overview
      • 2.3.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.3.2.1 Product A
        • 2.3.2.2 Product B
      • 2.3.3 Agilent Technologies Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.4 Astellas Pharmaceuticals
      • 2.4.1 Business Overview
      • 2.4.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.4.2.1 Product A
        • 2.4.2.2 Product B
      • 2.4.3 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.5 BAYER AG
      • 2.5.1 Business Overview
      • 2.5.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.5.2.1 Product A
        • 2.5.2.2 Product B
      • 2.5.3 BAYER AG Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.6 Bio Vision
      • 2.6.1 Business Overview
      • 2.6.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.6.2.1 Product A
        • 2.6.2.2 Product B
      • 2.6.3 Bio Vision Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.7 Celgene Corp.
      • 2.7.1 Business Overview
      • 2.7.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.7.2.1 Product A
        • 2.7.2.2 Product B
      • 2.7.3 Celgene Corp. Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.8 Emd Millipore
      • 2.8.1 Business Overview
      • 2.8.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.8.2.1 Product A
        • 2.8.2.2 Product B
      • 2.8.3 Emd Millipore Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.9 Epigenomics AG
      • 2.9.1 Business Overview
      • 2.9.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.9.2.1 Product A
        • 2.9.2.2 Product B
      • 2.9.3 Epigenomics AG Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.10 Epigentex
      • 2.10.1 Business Overview
      • 2.10.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.10.2.1 Product A
        • 2.10.2.2 Product B
      • 2.10.3 Epigentex Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.11 Envivo Pharmaceuticals (Forum Pharmaceutricals)
      • 2.11.1 Business Overview
      • 2.11.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.11.2.1 Product A
        • 2.11.2.2 Product B
      • 2.11.3 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.12 Gilead Sciences
      • 2.12.1 Business Overview
      • 2.12.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.12.2.1 Product A
        • 2.12.2.2 Product B
      • 2.12.3 Gilead Sciences Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.13 Glaxosmithkline
      • 2.13.1 Business Overview
      • 2.13.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.13.2.1 Product A
        • 2.13.2.2 Product B
      • 2.13.3 Glaxosmithkline Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.14 Illumina Inc.
      • 2.14.1 Business Overview
      • 2.14.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.14.2.1 Product A
        • 2.14.2.2 Product B
      • 2.14.3 Illumina Inc. Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.15 Johnson & Johnson
      • 2.15.1 Business Overview
      • 2.15.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.15.2.1 Product A
        • 2.15.2.2 Product B
      • 2.15.3 Johnson & Johnson Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.16 Karus Therapeutics Limited
      • 2.16.1 Business Overview
      • 2.16.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.16.2.1 Product A
        • 2.16.2.2 Product B
      • 2.16.3 Karus Therapeutics Limited Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.17 Laboratory Corp. Of America Holdings
      • 2.17.1 Business Overview
      • 2.17.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.17.2.1 Product A
        • 2.17.2.2 Product B
      • 2.17.3 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.18 LES Laboratoires Servier
      • 2.18.1 Business Overview
      • 2.18.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.18.2.1 Product A
        • 2.18.2.2 Product B
      • 2.18.3 LES Laboratoires Servier Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.19 Merck
      • 2.19.1 Business Overview
      • 2.19.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.19.2.1 Product A
        • 2.19.2.2 Product B
      • 2.19.3 Merck Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.20 Naturewise Biotech & Medicals Corp.
      • 2.20.1 Business Overview
      • 2.20.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.20.2.1 Product A
        • 2.20.2.2 Product B
      • 2.20.3 Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.21 Novartis Pharma AG
      • 2.21.1 Business Overview
      • 2.2.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.21.2.1 Product A
        • 2.21.2.2 Product B
      • 2.21.3 Novartis Pharma AG Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.22 Oncolys Biopharma Inc.
      • 2.22.1 Business Overview
      • 2.22.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.22.2.1 Product A
        • 2.22.2.2 Product B
      • 2.22.3 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.23 Orchid Chemicals & Pharmaceuticals Limited
      • 2.23.1 Business Overview
      • 2.23.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.23.2.1 Product A
        • 2.23.2.2 Product B
      • 2.23.3 Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.24 Progen Pharmaceuticals Limited
      • 2.24.1 Business Overview
      • 2.24.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.24.2.1 Product A
        • 2.24.2.2 Product B
      • 2.24.3 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.25 Quest Diagnostics
      • 2.25.1 Business Overview
      • 2.25.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.25.2.1 Product A
        • 2.25.2.2 Product B
      • 2.25.3 Quest Diagnostics Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.26 Roche Holding AG
      • 2.26.1 Business Overview
      • 2.26.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.26.2.1 Product A
        • 2.26.2.2 Product B
      • 2.26.3 Roche Holding AG Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.27 Rubicon Genomics
      • 2.27.1 Business Overview
      • 2.27.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.27.2.1 Product A
        • 2.27.2.2 Product B
      • 2.27.3 Rubicon Genomics Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)
    • 2.28 Takeda Pharmaceutical Company Limited
      • 2.28.1 Business Overview
      • 2.28.2 Personalized Medicine and Epigenomics Type and Applications
        • 2.28.2.1 Product A
        • 2.28.2.2 Product B
      • 2.28.3 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Revenue, Gross Margin and Market Share (2017-2018)

    3 Global Personalized Medicine and Epigenomics Market Competition, by Players

    • 3.1 Global Personalized Medicine and Epigenomics Revenue and Share by Players (2014-2019)
    • 3.2 Market Concentration Rate
      • 3.2.1 Top 5 Personalized Medicine and Epigenomics Players Market Share
      • 3.2.2 Top 10 Personalized Medicine and Epigenomics Players Market Share
    • 3.3 Market Competition Trend

    4 Global Personalized Medicine and Epigenomics Market Size by Regions

    • 4.1 Global Personalized Medicine and Epigenomics Revenue and Market Share by Regions
    • 4.2 North America Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)
    • 4.3 Europe Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)
    • 4.4 Asia-Pacific Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)
    • 4.5 South America Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)
    • 4.6 Middle East and Africa Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)

    5 North America Personalized Medicine and Epigenomics Revenue by Countries

    • 5.1 North America Personalized Medicine and Epigenomics Revenue by Countries (2014-2019)
    • 5.2 USA Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)
    • 5.3 Canada Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)
    • 5.4 Mexico Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)

    6 Europe Personalized Medicine and Epigenomics Revenue by Countries

    • 6.1 Europe Personalized Medicine and Epigenomics Revenue by Countries (2014-2019)
    • 6.2 Germany Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)
    • 6.3 UK Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)
    • 6.4 France Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)
    • 6.5 Russia Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)
    • 6.6 Italy Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)

    7 Asia-Pacific Personalized Medicine and Epigenomics Revenue by Countries

    • 7.1 Asia-Pacific Personalized Medicine and Epigenomics Revenue by Countries (2014-2019)
    • 7.2 China Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)
    • 7.3 Japan Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)
    • 7.4 Korea Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)
    • 7.5 India Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)
    • 7.6 Southeast Asia Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)

    8 South America Personalized Medicine and Epigenomics Revenue by Countries

    • 8.1 South America Personalized Medicine and Epigenomics Revenue by Countries (2014-2019)
    • 8.2 Brazil Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)
    • 8.3 Argentina Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)
    • 8.4 Colombia Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)

    9 Middle East and Africa Revenue Personalized Medicine and Epigenomics by Countries

    • 9.1 Middle East and Africa Personalized Medicine and Epigenomics Revenue by Countries (2014-2019)
    • 9.2 Saudi Arabia Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)
    • 9.3 UAE Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)
    • 9.4 Egypt Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)
    • 9.5 Nigeria Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)
    • 9.6 South Africa Personalized Medicine and Epigenomics Revenue and Growth Rate (2014-2019)

    10 Global Personalized Medicine and Epigenomics Market Segment by Type

    • 10.1 Global Personalized Medicine and Epigenomics Revenue and Market Share by Type (2014-2019)
    • 10.2 Global Personalized Medicine and Epigenomics Market Forecast by Type (2019-2024)
    • 10.3 Reagents Revenue Growth Rate (2014-2024)
    • 10.4 Kits Revenue Growth Rate (2014-2024)
    • 10.5 Instruments Revenue Growth Rate (2014-2024)
    • 10.6 Enzymes Revenue Growth Rate (2014-2024)
    • 10.7 Services Revenue Growth Rate (2014-2024)

    11 Global Personalized Medicine and Epigenomics Market Segment by Application

    • 11.1 Global Personalized Medicine and Epigenomics Revenue Market Share by Application (2014-2019)
    • 11.2 Personalized Medicine and Epigenomics Market Forecast by Application (2019-2024)
    • 11.3 Oncology Revenue Growth (2014-2019)
    • 11.4 Non-Oncology Revenue Growth (2014-2019)
    • 11.5 Cancer Drug Technology Revenue Growth (2014-2019)

    12 Global Personalized Medicine and Epigenomics Market Size Forecast (2019-2024)

    • 12.1 Global Personalized Medicine and Epigenomics Market Size Forecast (2019-2024)
    • 12.2 Global Personalized Medicine and Epigenomics Market Forecast by Regions (2019-2024)
    • 12.3 North America Personalized Medicine and Epigenomics Revenue Market Forecast (2019-2024)
    • 12.4 Europe Personalized Medicine and Epigenomics Revenue Market Forecast (2019-2024)
    • 12.5 Asia-Pacific Personalized Medicine and Epigenomics Revenue Market Forecast (2019-2024)
    • 12.6 South America Personalized Medicine and Epigenomics Revenue Market Forecast (2019-2024)
    • 12.7 Middle East and Africa Personalized Medicine and Epigenomics Revenue Market Forecast (2019-2024)

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Methodology

      Epigenomics is the study of the complete set of epigenetic modifications on the genetic material of a cell, known as the epigenome. The field is analogous to genomics and proteomics, which are the study of the genome and proteome of a cell.

      Scope of the Report:
      The global Personalized Medicine and Epigenomics market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
      The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
      North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Personalized Medicine and Epigenomics.
      Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
      This report studies the Personalized Medicine and Epigenomics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Personalized Medicine and Epigenomics market by product type and applications/end industries.

      Market Segment by Companies, this report covers
      Abbott Laboratories
      Affymetrix
      Agilent Technologies
      Astellas Pharmaceuticals
      BAYER AG
      Bio Vision
      Celgene Corp.
      Emd Millipore
      Epigenomics AG
      Epigentex
      Envivo Pharmaceuticals (Forum Pharmaceutricals)
      Gilead Sciences
      Glaxosmithkline
      Illumina Inc.
      Johnson & Johnson
      Karus Therapeutics Limited
      Laboratory Corp. Of America Holdings
      LES Laboratoires Servier
      Merck
      Naturewise Biotech & Medicals Corp.
      Novartis Pharma AG
      Oncolys Biopharma Inc.
      Orchid Chemicals & Pharmaceuticals Limited
      Progen Pharmaceuticals Limited
      Quest Diagnostics
      Roche Holding AG
      Rubicon Genomics
      Takeda Pharmaceutical Company Limited

      Market Segment by Regions, regional analysis covers
      North America (United States, Canada and Mexico)
      Europe (Germany, France, UK, Russia and Italy)
      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
      South America (Brazil, Argentina, Colombia)
      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers
      Reagents
      Kits
      Instruments
      Enzymes
      Services

      Market Segment by Applications, can be divided into
      Oncology
      Non-Oncology
      Cancer Drug Technology

      Buy now